GlaxoSmithKline PLC

LON100:GSK, Aug 20, 12:06 UTC FTSE 100 real-time data - Disclaimer Currency in GBP

Latest LON100:GSK News

News

Is Neil Woodford wrong about British American Tobacco plc and GlaxoSmithKline plc?

GSK BATS

British American Tobacco has expanded quickly over the past decade, and when it completes the acquisition of peer Reynolds American, the company will be the largest tobacco company in the world. By acquiring Reynolds, British American has absorbed the last easy growth opportunity available to it, now opportunities for growth through acquisitions are virtually non-existent. GlaxoSmithKline currently yields 5.3% and the shares trade at a forward P/E of 13.3. Based on this valuation, the company looks attractive as an alternative to British American, even though Woodford has turned his back on the business. Indeed, as noted above, shares in Glaxo are currently trading at a forward P/E of 13.3, 26% below the global pharmaceutical sector median valuation of 18. Overall, while British American looks as if it is running out of puff, Glaxo still appears to offer value for investors, even though Neil Woodford is skeptical about the firm's outlook.

Read Full Details

Topics:
  • Business
  • Financial
News

First Manhattan Drops Position in GlaxoSmithKline

GSK

August 19, 2017. First Manhattan trimmed its position in stocks of GlaxoSmithKline (NYSE:GSK) by 21.7% through out the Fiscal Q2, based on the latest 13F document with the Security and Exchange Commission. First Manhattan Drops Position in GlaxoSmithKline. Berenberg Bank boosted GlaxoSmithKline from a “hold” recommendation to a “buy” recommendation in a analysis note on Fri morning, May 26th. Lastly, ValuEngine cut shares of GlaxoSmithKline from a “buy” recommendation to a “hold” recommendation in a analysis note on Fri morning, Jun 2nd.

Read Full Details

Story Sources

insidertradings.org
Topics:
  • Business
  • Financial
News

GlaxoSmithKline Becomes Oversold (GSK)

GSK

One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of GlaxoSmithKline plc (Symbol: GSK) entered into oversold territory, hitting an RSI reading of 27.3, after changing hands as low as $38.72 per share. By comparison, the current RSI reading of the S&P 500 ETF ( SPY ) is 40.0. A bullish investor could look at GSK's 27.3 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Find out what 9 other oversold stocks you need to know about ». The chart below shows the one year performance of GSK shares: Looking at the chart above, GSK's low point in its 52 week range is $37.20 per share, with $44.58 as the 52 week high point - that compares with a last trade of $38.80. According to the ETF Finder at ETF Channel, GSK makes up 4.64% of the Pharmaceutical ETF (Symbol: PPH) which is trading lower by about 0.4% on the day Friday.

Read Full Details

Story Sources

nasdaq.com
Topics:
  • Business
  • Financial
News

New report examines the vaccine market forecast 2017-2022

GSK MRK +2 more GSK MRK JNJ PFE

“Monovalent vaccines segment expected to hold the largest share of the market in 2017.”. “Conjugate vaccines are expected to dominate the market during the forecast period. Vaccine Market, By Type. Recommended Market Research Companies.

Read Full Details

Story Sources

whatech.com
Topics:
  • Business
  • Health
  • Financial
News

Halitosis treatment market Key Players - Colgate-Palmolive, GlaxoSmithKline, Johnson & Johnson, Listerine, Procter & Gamble Corporation, AstraZeneca, Forecast to 2023

GSK JNJ +2 more GSK JNJ AZN CL

Market Research Future Publish a New Report on - “Halitosis Treatment Market Research Report- Global Forecast till 2023”. Global halitosis treatment, manufacturers & suppliers. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Read Full Details

Story Sources

newsmaker.com.au
Topics:
  • Business
  • Health
News

GlaxoSmithKline plc or Imperial Brands plc: which FTSE 100 favourite will be first to slash its dividend? - AOL UK Money

GSK IMB

While the company's less profitable consumer healthcare division can take the strain for a while, there may come a point at which Glaxo is required to make the sort of sacrifice many investors wouldn't consider from a business with such defensive qualities. While some investors may feel uncomfortable holding shares in companies whose products can be both addictive and disease-causing, it's hard to deny that tobacco stocks have been some of the most rewarding to buy and hold in recent times. Will Glaxo and Imperial be forced to make a cut? Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Read Full Details

Story Sources

aol.co.uk
Topics:
  • Business
  • Health
  • Financial
  • Entertainment
News

GlaxoSmithKline plc or Imperial Brands plc: which FTSE 100 favourite will be first to slash its dividend?

GSK IMB

While the company's less profitable consumer healthcare division can take the strain for a while, there may come a point at which Glaxo is required to make the sort of sacrifice many investors wouldn't consider from a business with such defensive qualities. While some investors may feel uncomfortable holding shares in companies whose products can be both addictive and disease-causing, it's hard to deny that tobacco stocks have been some of the most rewarding to buy and hold in recent times. Will Glaxo and Imperial be forced to make a cut? Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
  • Entertainment
News

Asthma Inhaler Device Market Key Players - GSK, Merck & Co., Inc. , 3M , Aristopharma Ltd. , SRS PHARMACEUTICALS PVT. LTD. , Intas Pharmaceuticals Ltd, Forecast to 2022

GSK MMM

Market Research Future Publish a New Report on - “Global Asthma Inhaler Device Market Research Report- Forecast to 2022”. Asthma inhaler device Manufacturers. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Read Full Details

Story Sources

newsmaker.com.au
Topics:
  • Business
  • Health
  • Financial
  • Science
News

Wellbutrin Buyers Didn’t Show Harm By GSK, 3rd Circ. Says

GSK

Law360, Fort Wayne (August 17, 2017, 5:17 PM EDT) -- The Third Circuit on Thursday revealed the reasoning behind its decision earlier this month to affirm a win for GlaxoSmithKline PLC in litigation accusing it of stifling generic competition for Wellbutrin XL, saying the purchasers who brought the suit did not show they were injured by GSK. The direct and indirect purchasers of the drug accused GSK and Wellbutrin patent holder Biovail Corp. of delaying generic versions of the antidepressant by entering into illegal reverse payment settlements with generics companies in early 2007, but the buyers...

Read Full Details

Story Sources

law360.com
Topics:
  • Business
  • Health
  • Financial
News

UPDATE 2-Drugmaker Hikma trims sales forecasts, shares fall (HIK, TEVA, GSK, 4502)

GSK HIK

Aug 17 (Reuters) - Hikma Pharmaceuticals Plc on Thursday said 2017 revenue would be at the lower end of its forecasts, citing increased pricing pressures in the generic drug industry, sending its shares to a more than three-year low. The company also lowered full-year revenue guidance on Thursday for a second time in its generics business by $50 million to about $620 million in 2017. Hikma's initial forecast had been $800 million. British business begs for clarity after Brexit maelstrom (SRP, GSK, GFS)Reuters 7d. , DGE, FRES, GKN, GSK, INF, LLOY, RDSA, RIO, RTO)Reuters 8d.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Shufro Rose & Co. LLC Maintains Stake in GlaxoSmithKline PLC (GSK)

GSK

LLC’s holdings in GlaxoSmithKline PLC were worth $313,000 as of its most recent filing with the SEC. FMR LLC boosted its stake in shares of GlaxoSmithKline PLC by 11.7% in the first quarter. ValuEngine cut GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research report on Friday, June 2nd. Berenberg Bank upgraded GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research report on Friday, May 26th.

Read Full Details

Topics:
  • Business
  • Health
  • Financial
News

Global Hepatitis Vaccine Market – GSK, Sanofi, Merck & Co, Pfizer – The Exclusive Facts 24

GSK

The Exclusive Facts 24. Global Hepatitis Vaccine Market – GSK, Sanofi, Merck & Co, Pfizer. First of all, ” Global Hepatitis Vaccine Market 2017 ” report provides a basic overview of the Hepatitis Vaccine industry including definitions, classifications, applications and Hepatitis Vaccine industry chain structure. biz/global-hepatitis-vaccine-sales-market/#ert_pane1-2. Related information to Hepatitis Vaccine market- capacity, production, price, cost, revenue and contact information. Then, the report focuses on Global Hepatitis Vaccine market key players with information such as company profiles with product picture as well as specification.

Read Full Details

Story Sources

exclusivefacts24.com
Topics:
  • Business
  • Financial
News

Hikma Pharmaceuticals plc's pain could be GlaxoSmithKline plc's gain - AOL UK Money

GSK HIK +1 more GSK HIK VZ

Investors will surely be disappointed, but some cautiously optimistic comments regarding Hikma's Advair generic will go some way to soothing long-term fears. Sales of Advair, GlaxoSmithKline's (LSE: GSK) premier blockbuster drug, have held up better than expected since its patent expired back in 2016, because the Diskus delivery system it employs has been a tough one to crack for both Hikma and rivals Mylan and Novartis alike. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Read Full Details

Story Sources

aol.co.uk
Topics:
  • Business
  • Financial
News

Hikma Pharmaceuticals plc’s pain could be GlaxoSmithKline plc’s gain

GSK HIK +1 more GSK HIK VZ

Investors will surely be disappointed, but some cautiously optimistic comments regarding Hikma's Advair generic will go some way to soothing long-term fears. Sales of Advair, GlaxoSmithKline's (LSE: GSK) premier blockbuster drug, have held up better than expected since its patent expired back in 2016, because the Diskus delivery system it employs has been a tough one to crack for both Hikma and rivals Mylan and Novartis alike. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro.

Read Full Details

Topics:
  • Business
  • Financial
News

Paronychia treatment Market Key Players- Glaxosmithkline, Glenmark Generics, Teva, Glaxo Wellcome., Eli Lilly, Jonakayem Pharma Formulation Pvt. Ltd

GSK LLY

Paronychia treatment Market Key Players- Glaxosmithkline, Glenmark Generics, Teva, Glaxo Wellcome. The globally market for paronychia treatment is one of the steady growing markets. What are the key market trends? What is driving this market?

Read Full Details

Topics:
  • Business
  • Health
  • Financial